Table 4.
Pathological diagnoses at resection of Afirma results with cytological subtypes (N=225).
| Pathological Diagnoses after Surgery | |||||
|---|---|---|---|---|---|
| Benign | Malignant | ||||
| FNA Diagnosis | No.(%) | Diagnosis | No.(%) | Diagnosis | No.(%) |
|
| |||||
| Bethesda III (AUS/FLUS) | 139(61.8%) | Follicular adenoma | 14(10.1%) | cvPTC | 37(26.6%) |
| Adenomatoid nodule | 23(16.5%) | fvPTC | 34(24.5%) | ||
| Thyroiditis | 7(5.0%) | PTC with HC | 2(1.4%) | ||
| Graves' Disease | 2(1.4%) | feature | |||
| HCA | 4(2.9%); | FTC | 1(0.7%) | ||
| Chronic inflammation | 1(0.7%) | HCC | 1(0.7%) | ||
| Nodular hyperplasia | 12(8.6%) | Others | 1(0.7%) | ||
| Total | 63 | Total | 76 | ||
|
| |||||
| Bethesda IV (FN) | 77(34.2%) | Follicular adenoma | 10(13.0%) | cvPTC | 25(28.6%) |
| HCA | 17(22.1%) | fvPTC | 13(16.9%) | ||
| Adenomatoid nodule | 6(7.8%) | FTC | 1(1.3%) | ||
| Nodular hyperplasia | 1(1.3%) | HCC | 4(5.2%) | ||
| Total | 34 | Total | 43 | ||
|
| |||||
| Bethesda V (SM) | 9(4.0%) | None | fvPTC | 7(5.5%) | |
| Total | 0 | Others | 2(1.6%) | ||
| Total | 9 | ||||
|
| |||||
| All Categories | 225(100.0%) | 97 | 128 | ||
PTC, papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid cancer; AN, adenomatous/hyperplasic nodule; cvPTC, classic variant of papillary thyroid carcinoma; fvPTC, follicular variant of papillary thyroid carcinoma; NIFPTC, noninvasive follicular neoplasm with papillary-like nuclear features; PTC, HC feature; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma.